medsci-skills 4.1.0

package/skills/write-paper/references/journal_profiles/Stroke.md

@@ -0,0 +1,210 @@
+# Journal Profile: Stroke (AHA/ASA)
+
+## Basic Information
+
+- **Publisher:** American Heart Association / American Stroke Association (Wolters Kluwer / Lippincott)
+- **Society:** AHA / ASA
+- **Editor-in-Chief:** Argye E. Hillis
+- **Frequency:** Monthly
+- **Scope:** Full cerebrovascular spectrum across three science categories — Basic/Translational, Clinical, Population
+- **Open Access:** Hybrid (subscription + optional Gold OA with APC)
+- **Language:** American English
+- **Submission email:** stroke@strokeahajournal.org
+- **ISSN:** 0039-2499 (print) / 1524-4628 (online); ISSN-L 0039-2499
+- **Rejection rate:** approximately 50% at first review (AHA journal page)
+
+---
+
+## Scope — Covered Topics
+
+### Basic / Translational
+- Cerebrovascular biology, neurovascular unit, blood-brain barrier
+- Animal models of ischemic stroke, ICH, SAH
+- Neuroinflammation, neuroprotection, reperfusion injury
+- Stroke genetics, genomics, and biomarkers
+
+### Clinical
+- Acute ischemic stroke management (IV thrombolysis, endovascular therapy, imaging selection)
+- Intracerebral and subarachnoid hemorrhage
+- Transient ischemic attack and minor stroke
+- Secondary stroke prevention
+- Cerebral small vessel disease, vascular cognitive impairment
+- Neurorehabilitation and recovery
+- Pediatric stroke
+
+### Population
+- Stroke epidemiology, risk factors, global burden
+- Disparities in stroke care and outcomes
+- Health services research, stroke systems of care, implementation science
+
+---
+
+## Manuscript Types and Word Limits
+
+| Type | Body Word Limit | Abstract | Figures/Tables | References |
+|------|----------------|----------|----------------|------------|
+| Original Research | 5,000 | 300 (structured) | 8 combined | ≤50 |
+| Brief Report | 2,000 | 250 (structured) | 4 combined | ≤20 |
+| Research Letter | 750 | None | 1 combined | ≤5 |
+| Review / Progress Review | 8,000 | 250 (unstructured) | 6 (+ key figure JPG) | unlimited |
+| Emerging Therapy Critique | 2,500 | 250 | 4 | ≤30 |
+| Comments and Opinions | 3,000 | None | 2 | ≤30 |
+| Special Report | 8,000 | 250 | variable | variable |
+| Stroke Images (clinical) | 150 | None | 2 | ≤5 |
+| Stroke Images (basic) | 350 | None | 2 | ≤10 |
+| Illustrative Teaching Case | 2,000 | 150 | 4 | ≤20 |
+| InterSECT | 2,000 | 150 | 4 | ≤20 (max 5 authors) |
+| Editorial (invited) | 1,500 | None | 2 | ≤20 |
+| Letter to the Editor | 500 | None | 1 | ≤5 |
+
+*Verify exact current limits on the author instructions page before submission — AHA periodically updates its limits.*
+
+---
+
+## Abstract Requirements
+
+**Structured 300-word abstract for Original Research:**
+
+```
+Background: [Clinical question; rationale]
+Methods: [Study design, population, interventions/exposures, outcomes, statistical approach]
+Results: [Key numerical results with effect sizes and 95% CI]
+Conclusions: [Main conclusion; clinical or scientific implication]
+```
+
+Research Letters and Comments/Opinions submit without an abstract.
+
+---
+
+## Graphic Abstract (Required at Revision)
+
+At the revision stage, authors must submit a Graphic Abstract summarizing the key finding visually. AHA provides dimension and content guidelines on the author page — verify at time of revision.
+
+---
+
+## Domain-Specific Outcome Measures
+
+### For Acute Ischemic Stroke Clinical Studies
+
+- **Functional outcome at 90 days:** mRS (modified Rankin Scale); good outcome commonly mRS 0–2
+- **Recanalization:** mTICI for endovascular; TIMI for older IV tPA studies
+- **Symptomatic intracranial hemorrhage (sICH):** state definition (ECASS II, ECASS III, SITS-MOST, NINDS, or Heidelberg)
+- **Early neurological change:** NIHSS change at 24 hours, discharge
+- **Mortality at 90 days**
+
+### For Prevention / Epidemiology Studies
+
+- **Recurrent stroke (ischemic / hemorrhagic / any):** state composite definition
+- **MACE:** define components
+- **Time-to-event:** Kaplan-Meier + Cox proportional hazards (test PH assumption)
+
+### For Imaging Studies
+
+- **Diagnostic accuracy:** sensitivity, specificity, AUC with 95% CI
+- **Inter-rater agreement:** kappa or ICC
+- **Report reference standard** (follow-up imaging, clinical adjudication, autopsy)
+
+### For Basic / Translational Studies
+
+- **ARRIVE 2.0** compliance for animal experiments
+- **Sample-size justification** and randomization/blinding reporting
+- **Sex as a biological variable** reported explicitly (NIH policy)
+
+---
+
+## Required Sections
+
+1. **Introduction** — Background; knowledge gap; specific aim
+2. **Methods**
+   - Ethics: IRB/IACUC approval + informed consent or waiver
+   - Study design, setting, participants, timeframe
+   - Exposures, interventions, outcomes with explicit definitions
+   - Statistical analysis
+   - Reporting-guideline citation (STROBE / CONSORT / PRISMA / STARD / TRIPOD / ARRIVE)
+   - **Data Availability Statement — required**
+3. **Results**
+   - Participant flow, baseline characteristics
+   - Primary and secondary outcomes with effect sizes and 95% CI
+   - Subgroup and sensitivity analyses
+4. **Discussion** — with Limitations subsection
+5. **Conclusion**
+
+---
+
+## Reference Style
+
+- **Vancouver numbered system**
+- Superscript reference numbers in the text
+- List the **first 10 authors followed by "et al."** when there are more than 10 authors
+- Journal abbreviations per Index Medicus / NLM
+- Include DOI or PMID when available
+
+---
+
+## Statistical Reporting Expectations
+
+- Effect sizes with 95% CI — not p-values alone
+- State statistical software (name, version, key packages)
+- Time-to-event: Kaplan-Meier with log-rank; Cox regression with PH assumption check
+- Diagnostic accuracy: AUC with 95% CI (DeLong); sensitivity/specificity with Clopper-Pearson CI
+- Missing data handling: complete-case, multiple imputation, IPW — specify and justify
+- Basic/translational: sample-size justification, randomization, blinding, sex as biological variable
+
+---
+
+## Revision Process
+
+- 90-day window for major revision
+- Graphic Abstract required at revision
+- Cover Image submission encouraged for accepted manuscripts
+- AHA multi-journal transfer option for rejected manuscripts (ATVB, Circulation Research, Hypertension, S:VIN, JAHA) — editor-initiated
+
+---
+
+## Common Rejection Reasons
+
+1. **Scope/novelty insufficient** — incremental confirmatory work without clear advance
+2. **Underpowered single-center retrospective series** without external validation
+3. **Weak comparator / selection bias** in observational studies
+4. **Missing reporting-guideline checklist**
+5. **Outcome definition vagueness** — mRS, mTICI, sICH must be pre-specified and cited
+6. **Basic science:** insufficient mechanism, missing sex-as-biological-variable, poor ARRIVE compliance
+
+---
+
+## Author Guidelines URL
+
+https://www.ahajournals.org/stroke/author-instructions
+
+---
+
+## AI Writing Disclosure Policy
+
+Stroke (AHA journals) has an explicit generative-AI policy:
+
+1. **AI cannot be an author** (ICMJE) — AI tools cannot take responsibility for the work.
+2. **Generative AI is permitted with documentation.** List all AI tools used in the Acknowledgments.
+3. **When AI is used in research design, data analysis, or figure preparation,** describe it in the Methods section with sufficient detail for reproducibility (tool name, version, prompts where relevant).
+4. **Grammar and spell-check tools** do not require disclosure.
+5. **AI-based image generation or manipulation is prohibited** in scientific figures (angiograms, histology, brain imaging).
+6. **Corresponding author remains responsible** for the accuracy of any AI-assisted content, including references.
+
+Always re-check the AHA/ASA author instructions at submission for updates.
+
+---
+
+## Positioning
+
+Stroke (AHA) is appropriate when:
+- The work targets the global (primarily North American / European) stroke research community
+- The study spans basic, translational, clinical, or population science of cerebrovascular disease
+- Hybrid (subscription or optional Gold OA) publication is acceptable
+- The work has potential for cross-AHA journal transfer on rejection
+
+Stroke (AHA) is less appropriate for: purely interventional device / technical notes (consider JNIS), purely imaging-diagnostic work without cerebrovascular focus (consider AJNR, Neuroradiology), or Asia-Pacific-targeted work where no-APC OA is preferred (consider Journal of Stroke).
+
+---
+
+## Verification note
+
+Profile built 2026-04-19 from the Stroke author-instructions PDF set (7 files). Article-type limits, AI policy, Vancouver 10-author rule, 90-day revision window, and Graphic Abstract requirement were transcribed directly from the source PDFs. ISSN verified against ISSN Portal (https://portal.issn.org/resource/ISSN/1524-4628) on 2026-04-19: print 0039-2499, online 1524-4628, ISSN-L 0039-2499, publisher Lippincott Williams & Wilkins.

package/skills/write-paper/references/journal_profiles/The_BMJ.md

@@ -0,0 +1,121 @@
+# The BMJ
+
+## Journal Identity
+
+- **Full name**: The BMJ (formerly British Medical Journal)
+- **Abbreviation**: BMJ
+- **Publisher**: BMJ Group (British Medical Association)
+- **ISSN**: 0959-8138 (print), 1756-1833 (online)
+- **Frequency**: Continuous online + weekly print
+- **Impact Factor**: 93.7 (JCR 2023), ranked 3rd among general medical journals
+- **Open Access**: All research articles are open access
+- **Acceptance rate**: ~7% overall, ~4% for research articles
+- **Open peer review**: Yes (prepublication history posted if accepted)
+
+## Article Types Relevant to Medical Education
+
+### Research
+- Accepts original research in medical education
+- Structured abstract (Objectives, Design, Setting, Participants, Main outcome measures, Results, Conclusions)
+- Word limit: ~4000 words (body), excludes abstract/references/tables
+- Max 6 tables/figures
+- ICMJE compliant, Vancouver references [square brackets]
+- Requires: STROBE checklist, data sharing statement, summary box ("What is already known" / "What this study adds")
+- Mandatory: patient/public involvement (PPI) reporting, sex/gender disaggregation
+- ScholarOne submission system
+
+### Education (COMMISSIONED ONLY)
+- **Does NOT accept unsolicited submissions**
+- Must submit proposal via Education Article Proposal Form + Declaration of Financial Interests
+- Topics: common/serious conditions, international appeal, multi-specialty interest
+- Encourages patient involvement and co-production
+- Financial interests can disqualify authors
+
+## Key Requirements for ALL Manuscripts
+
+### Title page
+- Title with study design subtitle
+- Authors: names, ORCiD (mandatory for corresponding author), affiliations, positions
+- Single corresponding author with full address and email
+
+### Contributorship and guarantor
+- Contributorship statement (who did what: planning, conduct, reporting)
+- Identify guarantor(s) who accept full responsibility
+- Required statement: "The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted."
+
+### Competing interests
+- Declaration required from ALL authors before review
+- Authors with financial ties to industry cannot write clinical editorials
+- Use BMJ competing interest form
+
+### AI use policy
+- Applies to all content types, all formats (text, audio, video, images, data, diagrams)
+- Must disclose any AI tool use in manuscript preparation
+
+### Copyright
+- Authors retain copyright, grant exclusive licence to BMJ
+- Non-commercial author reuse without permission
+
+### Data sharing
+- Required for research articles
+- Must state data availability
+
+### Summary box (Research articles)
+- "What is already known on this topic" (2-3 bullet points)
+- "What this study adds" (2-3 bullet points)
+
+### Reporting guidelines
+- Observational studies: STROBE
+- Trials: CONSORT
+- Education QI: SQUIRE 2.0
+- Completed checklist uploaded with submission
+
+## Submission Process
+
+- Via ScholarOne: submit.bmj.com
+- Word preferred, figures as separate TIFF/JPEG/PDF files (not embedded)
+- Tables as separate Word files (no Excel)
+- Cover letter required
+- Can select alternative BMJ journal if rejected (transfer service)
+- First decision: 2-3 weeks (often days for desk reject)
+- Final decision: 8-10 weeks
+
+## Review Process
+
+1. Senior research editor screens on submission day
+2. ~50% desk rejected (insufficient originality, not general audience, topic outside scope)
+3. If promising → handling editor → external peer review + patient reviewer
+4. Research manuscript meeting: statistics editor + handling editor + 4-7 research editors
+5. Decisions: provisional acceptance, request revisions, rejection
+6. Open peer review: all reviews published with accepted article
+
+## Statistical Reporting
+
+- Dedicated statistics editor reviews all research articles.
+- Report exact p-values to 2-3 significant figures (e.g., P = .023); use P < .001 for values below that threshold.
+- 95% CI mandatory for all primary outcomes; report alongside (not instead of) p-values.
+- Absolute risk differences preferred over relative risks alone; report NNT where clinically meaningful.
+- Effect sizes with units required.
+- For observational studies: report both adjusted and unadjusted estimates.
+- Sex and gender disaggregation of results required (SAGER guidelines).
+- Avoid "significant" without accompanying statistics; use "statistically significant (P = .03)" or report the effect size with CI.
+- Statistical software and version must be identified in Methods.
+
+## Strategic Notes for an education-research manuscript
+
+- **Education section**: NOT suitable (commissioned only, proposal required)
+- **Research section**: Theoretically possible but very competitive (4% acceptance)
+  - Would need to frame as having broad relevance beyond radiology
+  - Pilot study with n=24 likely too small for The BMJ Research
+  - Null primary findings reduce appeal for high-impact general journal
+- **Alternative BMJ journals**: BMJ Open (IF ~3.0, more realistic), or stay with BMC Medical Education
+- **Transfer service**: If rejected from The BMJ, can transfer to BMJ Open automatically
+
+---
+
+## AI Writing Disclosure Policy
+- **Requirement level:** Required
+- **Permitted scope:** All tasks — AI tools may be used for writing, editing, and other manuscript preparation tasks, but cannot be listed as authors; authors are accountable for all content including AI-generated text; follows ICMJE + COPE guidance
+- **Disclosure location:** Methods + Acknowledgments — must disclose the AI tool name, version, and how it was used; applies to all content types (text, audio, video, images, data, diagrams)
+- **AI-generated images:** Must be declared — AI-generated or AI-manipulated images, diagrams, and data visualizations must be explicitly disclosed; not blanket banned but full transparency required
+- **Policy URL:** https://www.bmj.com/company/the-bmjs-position-on-ai-and-large-language-models/

package/skills/write-paper/references/journal_profiles/The_Lancet.md

@@ -0,0 +1,112 @@
+# The Lancet
+
+## Journal Identity
+
+- **Full name**: The Lancet
+- **Abbreviation**: Lancet
+- **Publisher**: Elsevier (The Lancet Group)
+- **ISSN**: 0140-6736
+- **Frequency**: Weekly
+- **Impact Factor**: Among the highest in general medicine
+- **Open Access**: Hybrid (The Lancet Digital Health is fully OA; The Lancet offers OA options)
+- **APC**: See Lancet OA policies
+
+## Manuscript Types and Word Limits
+
+| Type | Abstract | Manuscript Body | References | Figures/Tables |
+|------|----------|----------------|------------|----------------|
+| Article | 300 w (structured) | 3,500 (4,500 for RCTs) | 30 | 5 |
+| Review | 150 w (unstructured) | 4,500 | 75 | 5-6 encouraged |
+| Comment | None | 750 | 10 | 1 |
+| Correspondence | None | 400 | 5 | 1 |
+| Viewpoint | None | 2,500 | 30 | Varies |
+
+Word counts exclude abstract, references, tables, and figure legends.
+
+## Abstract Format
+
+Structured with five headings (for Articles):
+1. **Background**
+2. **Methods**
+3. **Findings**
+4. **Interpretation**
+5. **Funding**
+
+Maximum 300 words. No references. RCT abstracts: include recruitment dates, group sizes with sex breakdown, primary outcome with effect size and CI, adverse events.
+
+## Keywords
+
+Not required (Lancet journals handle indexing internally).
+
+## Required Sections
+
+1. **Introduction**
+2. **Methods** (end with "Role of the funding source" subheading)
+3. **Results** (no subheadings for RCTs)
+4. **Discussion** (no subheadings for RCTs)
+
+Mandatory additional elements:
+- **Research in Context panel**: Evidence before this study (with search strategy), Added value, Implications
+- **Data Sharing Statement**: must specify what/when/where/with whom/how; "undecided" not acceptable
+- **Contributors**: specific contributions per author; at least one must verify underlying data
+- **Declaration of Interests** (ICMJE form, covering past 3 years)
+- **Role of the Funding Source** statement
+
+## Citation Style
+
+- Vancouver (numbered) style with superscript numbers after punctuation
+- Two refs: comma, no space (e.g., ^1,2); three+ consecutive: en-dash (e.g., ^1-3)
+- 6 or fewer authors: list all; 7+: first 3 then "et al."
+- Journal abbreviations per Index Medicus
+- No references in Summary, Research in Context, or Search strategy panels
+- Preprints: mark as "[preprint]" before reference
+
+## Reporting Guidelines
+
+| Study Type | Required Guideline |
+|------------|-------------------|
+| Randomized trials | CONSORT 2025 |
+| AI intervention trials | CONSORT-AI |
+| Observational studies | STROBE |
+| Diagnostic accuracy | STARD |
+| Systematic reviews | PRISMA |
+| AI/ML studies | CLAIM, TRIPOD+AI |
+| Genetic associations | STREGA |
+| Global health estimates | GATHER |
+| Sex/gender reporting | SAGER |
+
+## Statistical Reporting
+
+Strict in-house statistical conventions enforced by statistical editors:
+- Exact p-values to 2 significant figures (e.g., P = .023); cap at P < .0001.
+- 95% CI required for all primary outcomes; report alongside (not instead of) p-values.
+- Means with SDs for normal distributions; medians with IQRs for skewed data.
+- Absolute risk differences required alongside relative measures (RR, OR, HR).
+- RCT abstracts: include effect size with CI and p-value for primary outcome; adverse events quantified.
+- Decimal separator: midline dot (·) per Lancet house style.
+- Sex/gender disaggregated results required per SAGER guidelines.
+- Statistical editors review all accepted manuscripts.
+- Statistical software and version must be identified in Methods.
+
+## Special Notes
+
+- **Single-blind peer review**; most papers rejected at editorial triage.
+- **All figures redrawn** into Lancet style by in-house illustrators; submit editable vector files.
+- **Decimal points**: use midline dots (·), not periods.
+- **Serial comma required** before final "and"/"or".
+- **Drug names**: use rINN (recommended international non-proprietary name).
+- **Supplementary material**: single PDF with table of contents, numbered pages, references numbered separately.
+- **Proofs**: must return within 48 hours; no stylistic changes permitted.
+- **Sex/gender/race/ethnicity**: detailed reporting required per SAGER guidelines; explain data collection methods in Methods.
+- **AI policy**: generative AI only for readability/language; disclose in Acknowledgments with tool name, version, exact prompts.
+- **Author signatures** from all authors required before publication.
+- **Tables**: supply in separate Word document (not Excel/PDF); do not merge cells.
+
+---
+
+## AI Writing Disclosure Policy
+- **Requirement level:** Required
+- **Permitted scope:** Language editing only — generative AI may be used only for readability and language improvement; AI cannot be listed as an author; authors are fully responsible for accuracy of all content
+- **Disclosure location:** Acknowledgments — must disclose the AI tool name, version, and the exact prompts used; also reference in the cover letter
+- **AI-generated images:** Banned — Elsevier policy explicitly prohibits use of generative AI or AI-assisted tools to create or alter images in submitted manuscripts (including enhancing, obscuring, moving, removing, or introducing features); AI-generated artwork and graphical abstracts also not permitted; sole exception is when AI imaging is part of the research methodology itself (e.g., biomedical imaging research), which must be fully described in Methods; The Lancet further restricts AI use to language/readability only (Elsevier policy; confirmed Apr 2026)
+- **Policy URL:** https://www.thelancet.com/publishing-with-the-lancet

package/skills/write-paper/references/journal_profiles/The_Lancet_Digital_Health.md

@@ -0,0 +1,104 @@
+# The Lancet Digital Health
+
+## Journal Identity
+
+- **Full name**: The Lancet Digital Health
+- **Abbreviation**: Lancet Digit Health
+- **Publisher**: Elsevier (The Lancet Group)
+- **ISSN**: 2589-7500
+- **Frequency**: Monthly
+- **Impact Factor**: ~24.1 (2024)
+- **Open Access**: Yes (Gold OA, CC BY 4.0 default)
+- **APC**: See https://www.thelancet.com/publishing-open-access
+
+## Manuscript Types and Word Limits
+
+| Type | Abstract | Manuscript Body | References | Figures/Tables |
+|------|----------|----------------|------------|----------------|
+| Article | 300 w (structured) | 3,500 | 30 | 5 combined |
+| Review | 300 w | 5,000 | 100 | 5 |
+| Comment | None | 1,500 | 15 | 1 |
+| Correspondence | None | 500 | 5 | 1 |
+| Viewpoint | None | 2,000 | 20 | 2 |
+
+Word counts exclude abstract, references, tables, and figure legends.
+
+## Abstract Format
+
+Structured with five headings (for Articles):
+1. **Background**
+2. **Methods**
+3. **Findings**
+4. **Interpretation**
+5. **Funding**
+
+Maximum 300 words. No references in abstract.
+
+## Keywords
+
+Not required (indexing handled by editorial team).
+
+## Required Sections
+
+1. **Introduction**
+2. **Methods** (include AI model details for AI/ML studies)
+3. **Results**
+4. **Discussion**
+
+Mandatory additional elements:
+- **Research in Context panel** (after abstract): Evidence before this study, Added value of this study, Implications of all the available evidence
+- **Role of the Funding Source** statement
+- **Contributors** (specific contributions per author)
+- **Declaration of Interests** (ICMJE form)
+- **Data Sharing Statement** (what, when, where, with whom, how)
+- **Code Availability** (encouraged for AI/ML studies)
+
+## Citation Style
+
+- Vancouver (numbered) style with superscript numbers
+- Superscript after punctuation; consecutive numbers with en-dash (e.g., ^1-3,7)
+- 6 or fewer authors: list all; 7+: first 3 then "et al."
+- Use PubMed/MEDLINE journal abbreviations
+- Include DOI where available
+- No "Ibid." or "op. cit."
+
+## Reporting Guidelines
+
+| Study Type | Required Guideline |
+|------------|-------------------|
+| Randomized trials | CONSORT |
+| AI intervention trials | CONSORT-AI |
+| Observational studies | STROBE |
+| Diagnostic accuracy | STARD |
+| Systematic reviews | PRISMA |
+| Prediction models | TRIPOD (+AI extension) |
+| AI/ML studies | CLAIM |
+| Qualitative research | SRQR or COREQ |
+| Quality improvement | SQUIRE |
+
+Completed checklist with page numbers must be uploaded at submission.
+
+## Statistical Reporting
+
+Follows Lancet Group statistical conventions:
+- Exact p-values to 2 significant figures (e.g., P = .023); cap at P < .0001.
+- 95% CI required for all primary outcomes; report as (lower--upper) with en-dash.
+- Means with SDs for normally distributed data; medians with IQRs for skewed data.
+- For AI/ML studies: discrimination (AUC/C-statistic with 95% CI) and calibration (calibration plot minimum) required.
+- TRIPOD+AI or CLAIM checklist compliance is mandatory for AI studies; statistical reporting must align with checklist items.
+- For diagnostic accuracy: sensitivity, specificity, PPV, NPV, likelihood ratios -- all with 95% CI.
+- Decimal separator: midline dot (·) per Lancet house style.
+- Statistical software and version must be identified in Methods.
+
+## Special Notes
+
+- **Ranked #1** in medical informatics by IF and CiteScore.
+- **Single-blind peer review**; triage decision in 1-2 weeks; full review 4-8 weeks.
+- **Research in Context panel mandatory** for all Articles: must include systematic search strategy.
+- **Supplementary appendix**: single PDF, not copyedited, referenced as "(appendix p X)".
+- **Line numbering**: continuous throughout manuscript.
+- **Decimal points**: use midline dots (ALT+0183 on PC; ALT+SHIFT+9 on Mac).
+- **Preprints allowed**: disclose at submission; update with link upon acceptance.
+- **AI disclosure**: in Methods or Acknowledgements; AI tools cannot be authors.
+- **Transfer between Lancet journals** available if not suitable for this journal.
+- Figures redrawn into Lancet style by in-house illustrators.

package/skills/write-paper/references/journal_profiles/World_Journal_of_Hepatology.md

@@ -0,0 +1,106 @@
+# Journal Profile: World Journal of Hepatology
+
+## Journal Identity
+- **Full name:** World Journal of Hepatology
+- **Abbreviation:** World J Hepatol
+- **Publisher:** Baishideng Publishing Group Inc., Pleasanton, CA, USA
+- **ISSN:** 1948-5182 (online-only)
+- **Frequency:** Continuous online publication
+- **Open Access:** Mandatory full OA, **CC BY-NC 4.0** (no commercial reuse, no AI-training reuse)
+- **Acceptance rate:** ~30–40 % (estimated; verify at journal site)
+- **Peer review:** External anonymous peer review by ≥ 2 reviewers; in-house editor selects reviewers; 17-step editorial workflow.
+
+## Manuscript Types and Word Limits
+
+Each study design has its own dedicated writing guidelines URL on the BPG site. Article types relevant to retrospective hepatology cohort work:
+
+| Type (BPG section #) | Detailed writing guide |
+|---|---|
+| Retrospective Cohort Study (3.11) | https://www.wjgnet.com/bpg/GerInfo/210 |
+| Retrospective Study (3.12) | https://www.wjgnet.com/bpg/GerInfo/211 |
+| Observational Study (3.14) | https://www.wjgnet.com/bpg/GerInfo/200 |
+| Prospective Study (3.15) | https://www.wjgnet.com/bpg/GerInfo/201 |
+| Clinical Trials Study (3.13) | https://www.wjgnet.com/bpg/GerInfo/196 |
+| RCT (3.16) | https://www.wjgnet.com/bpg/GerInfo/209 |
+| Randomized Clinical Trial (3.17) | https://www.wjgnet.com/bpg/GerInfo/202 |
+| Case-Control Study (3.10) | https://www.wjgnet.com/bpg/GerInfo/195 |
+| Basic Study (3.18) | https://www.wjgnet.com/bpg/GerInfo/218 |
+| Evidence-Based Medicine (3.19) | https://www.wjgnet.com/bpg/GerInfo/198 |
+| Systematic Review (3.20) | https://www.wjgnet.com/bpg/GerInfo/203 |
+| Meta-Analysis (3.21) | https://www.wjgnet.com/bpg/GerInfo/278 |
+| Case Report (3.23) | https://www.wjgnet.com/bpg/GerInfo/187 |
+| Editorial / Frontier / Field of Vision / Opinion / Expert Consensus / Evidence Review / Review / Minireview | various GerInfo URLs |
+| Correspondence / Letter to Editor (3.24) | https://www.wjgnet.com/bpg/GerInfo/219 |
+
+Word limits, abstract format, and reference caps are defined per article type at each URL above — there is no single shared word limit across types.
+
+## Abstract Requirements
+Per article type. Retrospective Cohort Study and Observational Study guides require structured abstracts (Background, Aim, Methods, Results, Conclusions) with explicit study design label.
+
+## Required Sections
+Standard IMRAD per study-type guide. Core elements:
+1. **Title page** (concise informative title; running title; full author names and affiliations; corresponding author with email)
+2. **Abstract** (structured per article type)
+3. **Keywords**
+4. **Core Tip** (3–5 sentence summary, Baishideng-specific element placed after Abstract)
+5. **Introduction**
+6. **Materials and Methods**
+7. **Results**
+8. **Discussion**
+9. **Article Highlights** (4-paragraph structured: Background, Research motivation, Research objectives, Research methods, Research results, Research conclusions, Research perspectives) — Baishideng-specific
+10. **Acknowledgements**
+11. **Footnote / Conflict-of-Interest / Informed-consent / Institutional-review-board / Helsinki / STROBE compliance statements** (Baishideng-specific footnote block)
+12. **References** (Vancouver, with PMID and DOI for every entry)
+13. **Tables / Figures**
+
+## Statistical Reporting
+- Statistical methods named with software and version.
+- Reporting guideline named in Methods (STROBE for cohort/observational; STARD for diagnostic accuracy; PRISMA for SR/MA; CONSORT for RCT; ARRIVE for animals; CARE for case reports).
+- 95% CI mandatory; effect sizes with measures of variability.
+
+## Figures
+- High-resolution TIFF / EPS / PNG, ≥ 300 dpi.
+- Color allowed (OA supports color at no extra charge).
+- All figures must have CC BY-NC 4.0-compatible permissions if reproducing prior work.
+
+## Common Rejection Reasons
+1. Submission outside the wjgnet/F6Publishing platform (no email submissions accepted).
+2. Missing Article Highlights or Core Tip block (Baishideng-specific).
+3. References without PMID or DOI for indexed sources.
+4. Inadequate ethics block in footnote (CoI / IRB / Helsinki / STROBE compliance) — manuscript returned without review.
+5. Word/format violations of the article-type-specific writing guide.
+
+## Cover Letter
+Submission via F6Publishing (https://www.f6publishing.com). Cover letter should:
+- Quote manuscript ID after assignment.
+- Confirm originality and CC BY-NC 4.0 acceptance.
+- Note any prior peer review at sister BPG journal (transfer is supported).
+
+## AI Writing Disclosure Policy
+- **Requirement level:** Required (BPG declares ICMJE conformity).
+- **Permitted scope:** AI tools may not be authors; AI use disclosed in Methods.
+- **Special note:** BPG explicitly reserves rights against AI-training reuse: "All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply" — i.e., CC BY-NC 4.0 prohibits commercial AI training on these articles.
+- **Disclosure location:** Methods + Acknowledgements.
+- **Policy URL:** https://www.wjgnet.com/bpg/gerinfo/287 (ICMJE conformity statement; verify)
+
+## Author Guidelines URL
+https://www.wjgnet.com/bpg/gerinfo/204 (BPG common guide; first published 2017-05-02, last updated 2026-03-24)
+
+Submission portal: https://www.f6publishing.com
+Help desk: https://www.f6publishing.com/helpdesk
+Contact: editorialoffice@wjgnet.com (general); j.l.wang@wjgnet.com (peer-review appeals); j.p.yan@wjgnet.com (revision/second-decision appeals)
+
+## Positioning
+
+**When to submit here.** Korean / Asian / global retrospective hepatology cohort studies, MASLD natural history, observational studies, biomarker validation, and basic hepatology research that wants fast OA dissemination, accepts CC BY-NC 4.0, and is willing to follow Baishideng's article-type-specific structural requirements (Core Tip, Article Highlights, dedicated writing guide per study design). Useful as a **secondary fallback** when authors want a Q3-tier OA hepatology venue with broader acceptance bandwidth than CMH / Hepatology International. APC is typically cheaper than full-OA AASLD/Springer venues.
+
+**When NOT to submit here.** Studies that need top-tier indexing impact (Q1) — World J Hepatol historically sits Q3-Q4. Authors who require CC BY (BPG mandates CC BY-NC). Manuscripts whose data the authors plan to license commercially or feed into AI training (CC BY-NC blocks both). Studies under embargo from another society where transfer to BPG is not permitted.
+
+| Dimension | World J Hepatol | World J Gastroenterol | Hepatol Comm | CMH |
+|---|---|---|---|---|
+| Publisher | Baishideng | Baishideng | Wolters Kluwer/AASLD | KASL |
+| Tier | Q3–Q4 | Q1–Q2 | Q1 | Q1 (KASL flagship) |
+| OA license | CC BY-NC 4.0 | CC BY-NC 4.0 | CC BY or CC BY-NC-ND | CC BY |
+| Acc. rate (est.) | ~30–40 % | ~30–35 % | ~30–35 % | ~25–30 % |
+| Hepatology focus | Dedicated | Broad GI/Hep | Dedicated | Dedicated |
+| AI-training reuse | Prohibited | Prohibited | Permitted (CC BY) | Permitted (CC BY) |